Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coronado Biosciences has reported positive results from preclinical trials, which showed that the Bcl-2 inhibitor, Apogossypol, effectively killed a variety of cancer cells in vitro while demonstrating less toxicity than Gossypol in vivo in mice.
Subscribe to our email newsletter
The study findings demonstrate that mice treated with Apogossypol experienced less hepatotoxicity and gastrointestinal toxicity than those treated with Gossypol. The results support Coronado Biosciences’ continued development of its lead candidate, CNDO103, as a cancer treatment.
RJ Tesi, president and CEO of Coronado Biosciences, said: “We plan to perform IND-enabling preclinical studies for Apogossypol, CNDO103, in the first half of 2008. If the toxicity profile in animals approximates what was shown in this work, we plan to file an IND in late 2008.”